|
|
|
|
|
|
|
|
|
|
FDA Approves Bevacizumab for Platinum-Sensitive Ovarian Cancer
Tuesday, Dec 06, 2016
Specifically, the new indication supports the use of bevacizumab either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by bevacizumab alone, for patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, Genentech said.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.